Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
123755432 | 12375543 | 2 | F | 20160422 | 20160826 | 20160517 | 20160902 | EXP | FR-PFIZER INC-2016252684 | PFIZER | 60.00 | YR | F | Y | 0.00000 | 20160902 | OT | FR | FR |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
123755432 | 12375543 | 1 | PS | TAHOR | ATORVASTATIN CALCIUM | 1 | Oral | 10 MG, DAILY | Y | 20702 | 10 | MG | FILM-COATED TABLET | ||||||
123755432 | 12375543 | 2 | SS | COLCHIMAX (FRANCE) | COLCHICINEOPIUM, POWDEREDTIEMONIUM | 1 | Oral | UNK | Y | 0 | FILM-COATED TABLET | ||||||||
123755432 | 12375543 | 3 | SS | COLCHIMAX (FRANCE) | COLCHICINEOPIUM, POWDEREDTIEMONIUM | 1 | 0.5 MG, DAILY | Y | 0 | .5 | MG | FILM-COATED TABLET | |||||||
123755432 | 12375543 | 4 | SS | ZYLORIC | ALLOPURINOL | 1 | 100 MG, DAILY | Y | 0 | 100 | MG | ||||||||
123755432 | 12375543 | 5 | SS | ZYLORIC | ALLOPURINOL | 1 | UNK | Y | 0 | ||||||||||
123755432 | 12375543 | 6 | C | KARDEGIC | ASPIRIN LYSINE | 1 | 160 MG, DAILY | 0 | 160 | MG | |||||||||
123755432 | 12375543 | 7 | C | CYMBALTA | DULOXETINE HYDROCHLORIDE | 1 | 60 MG, DAILY | 0 | 60 | MG | |||||||||
123755432 | 12375543 | 8 | C | COAPROVEL | HYDROCHLOROTHIAZIDEIRBESARTAN | 1 | 1 DF (DOSAGE FORM), DAILY | 0 | 1 | DF | |||||||||
123755432 | 12375543 | 9 | C | TEMERIT | NEBIVOLOL | 1 | 2.5 MG, DAILY | 0 | 2.5 | MG | |||||||||
123755432 | 12375543 | 10 | C | INEXIUM | ESOMEPRAZOLE | 1 | 20 MG, DAILY | 0 | 20 | MG | |||||||||
123755432 | 12375543 | 11 | C | DAFALGAN | ACETAMINOPHEN | 1 | UNK, AS NEEDED | 0 | |||||||||||
123755432 | 12375543 | 12 | C | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | 500 MG, 2X/DAY (TWICE DAILY) | 0 | 500 | MG | BID | ||||||||
123755432 | 12375543 | 13 | C | GALVUS | VILDAGLIPTIN | 1 | 50 MG, DAILY | 0 | 50 | MG | |||||||||
123755432 | 12375543 | 14 | C | LANTUS | INSULIN GLARGINE | 1 | 20 IU, 1X/DAY (THE EVENING) | 0 | 20 | IU | QD | ||||||||
123755432 | 12375543 | 15 | C | APIDRA | INSULIN GLULISINE | 1 | 9 IU IN THE MORNING, 8 IU AT MIDDAY AND 12 IU IN THE EVENING | 0 | 29 | IU |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
123755432 | 12375543 | 1 | Hypercholesterolaemia |
123755432 | 12375543 | 2 | Gout |
123755432 | 12375543 | 4 | Gout |
123755432 | 12375543 | 12 | Type 2 diabetes mellitus |
123755432 | 12375543 | 13 | Type 2 diabetes mellitus |
123755432 | 12375543 | 14 | Type 2 diabetes mellitus |
123755432 | 12375543 | 15 | Type 2 diabetes mellitus |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
123755432 | 12375543 | HO |
123755432 | 12375543 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
123755432 | 12375543 | Acute prerenal failure | |
123755432 | 12375543 | Cell death | |
123755432 | 12375543 | Cholestasis | |
123755432 | 12375543 | Rhabdomyolysis |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
123755432 | 12375543 | 1 | 20160423 | 0 | ||
123755432 | 12375543 | 2 | 20160307 | 20160422 | 0 | |
123755432 | 12375543 | 4 | 20160307 | 20160423 | 0 | |
123755432 | 12375543 | 12 | 201603 | 20160425 | 0 | |
123755432 | 12375543 | 13 | 201603 | 20160425 | 0 | |
123755432 | 12375543 | 14 | 201603 | 0 | ||
123755432 | 12375543 | 15 | 201603 | 0 |